These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

187 related articles for article (PubMed ID: 19698012)

  • 1. Argatroban dosage requirements and outcomes in intensive care versus non-intensive care patients.
    Smythe MA; Koerber JM; Forsyth LL; Priziola JL; Balasubramaniam M; Mattson JC
    Pharmacotherapy; 2009 Sep; 29(9):1073-81. PubMed ID: 19698012
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Argatroban therapy in heparin-induced thrombocytopenia with hepatic dysfunction.
    Levine RL; Hursting MJ; McCollum D
    Chest; 2006 May; 129(5):1167-75. PubMed ID: 16685006
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Argatroban anticoagulation for heparin-induced thrombocytopenia in elderly patients.
    Bartholomew JR; Pietrangeli CE; Hursting MJ
    Drugs Aging; 2007; 24(6):489-99. PubMed ID: 17571914
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Argatroban therapy for heparin-induced thrombocytopenia in ICU patients with multiple organ dysfunction syndrome: a retrospective study.
    Saugel B; Phillip V; Moessmer G; Schmid RM; Huber W
    Crit Care; 2010; 14(3):R90. PubMed ID: 20487559
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Risk factors for major bleeding in patients with heparin-induced thrombocytopenia treated with argatroban: a retrospective study.
    Hursting MJ; Verme-Gibboney CN
    J Cardiovasc Pharmacol; 2008 Dec; 52(6):561-6. PubMed ID: 19057393
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparison of bivalirudin and argatroban for the management of heparin-induced thrombocytopenia.
    Skrupky LP; Smith JR; Deal EN; Arnold H; Hollands JM; Martinez EJ; Micek ST
    Pharmacotherapy; 2010 Dec; 30(12):1229-38. PubMed ID: 21114390
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Argatroban anticoagulation in patients with heparin-induced thrombocytopenia requiring renal replacement therapy.
    Reddy BV; Grossman EJ; Trevino SA; Hursting MJ; Murray PT
    Ann Pharmacother; 2005 Oct; 39(10):1601-5. PubMed ID: 16131539
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of renal function on argatroban therapy in heparin-induced thrombocytopenia.
    Guzzi LM; McCollum DA; Hursting MJ
    J Thromb Thrombolysis; 2006 Dec; 22(3):169-76. PubMed ID: 17103051
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Weight-based argatroban dosing nomogram for treatment of heparin-induced thrombocytopenia.
    Ansara AJ; Arif S; Warhurst RD
    Ann Pharmacother; 2009 Jan; 43(1):9-18. PubMed ID: 19126826
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Stroke in patients with heparin-induced thrombocytopenia and the effect of argatroban therapy.
    LaMonte MP; Brown PM; Hursting MJ
    Crit Care Med; 2004 Apr; 32(4):976-80. PubMed ID: 15071388
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Evaluation of treatment with direct thrombin inhibitors in patients with heparin-induced thrombocytopenia.
    Dang CH; Durkalski VL; Nappi JM
    Pharmacotherapy; 2006 Apr; 26(4):461-8. PubMed ID: 16553503
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Argatroban therapy for heparin-induced thrombocytopenia in acutely ill patients.
    Gray A; Wallis DE; Hursting MJ; Katz E; Lewis BE
    Clin Appl Thromb Hemost; 2007 Oct; 13(4):353-61. PubMed ID: 17911186
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Evaluation of diagnostic tests and argatroban or lepirudin therapy in patients with suspected heparin-induced thrombocytopenia.
    Kiser TH; Jung R; MacLaren R; Fish DN
    Pharmacotherapy; 2005 Dec; 25(12):1736-45. PubMed ID: 16305293
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effects of critical illness and organ failure on therapeutic argatroban dosage requirements in patients with suspected or confirmed heparin-induced thrombocytopenia.
    Keegan SP; Gallagher EM; Ernst NE; Young EJ; Mueller EW
    Ann Pharmacother; 2009 Jan; 43(1):19-27. PubMed ID: 19116377
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Argatroban anticoagulation in intensive care patients: effects of heart failure and multiple organ system failure.
    Begelman SM; Baghdasarian SB; Singh IM; Militello MA; Hursting MJ; Bartholomew JR
    J Intensive Care Med; 2008; 23(5):313-20. PubMed ID: 18701526
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Argatroban therapy in women with heparin-induced thrombocytopenia.
    Jang IK; Baron SJ; Hursting MJ; Anglade E
    J Womens Health (Larchmt); 2007; 16(6):895-901. PubMed ID: 17678460
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Evaluation of a standardized protocol using lepirudin or argatroban for heparin-induced thrombocytopenia.
    Kennedy K; Steinke D; King S; Poe K; Reeves J; Short M
    Cardiovasc Hematol Agents Med Chem; 2011 Oct; 9(4):262-8. PubMed ID: 21902659
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Reducing harm associated with anticoagulation: practical considerations of argatroban therapy in heparin-induced thrombocytopenia.
    Hursting MJ; Soffer J
    Drug Saf; 2009; 32(3):203-18. PubMed ID: 19338378
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Recognition of heparin-induced thrombocytopenia and initiation of argatroban therapy after cardiothoracic surgery in the intensive care unit.
    Demma LJ; Paciullo CA; Levy JH
    J Thorac Cardiovasc Surg; 2012 May; 143(5):1213-8. PubMed ID: 22329977
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Argatroban therapy in pediatric patients requiring nonheparin anticoagulation: an open-label, safety, efficacy, and pharmacokinetic study.
    Young G; Boshkov LK; Sullivan JE; Raffini LJ; Cox DS; Boyle DA; Kallender H; Tarka EA; Soffer J; Hursting MJ
    Pediatr Blood Cancer; 2011 Jul; 56(7):1103-9. PubMed ID: 21488155
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.